Genentech

Questex LLC | September 17, 2018

When it comes to antibiotic-resistant bacteria, so-called Gram-negative bugs are the most worrisome to scientists and drug developers. That’s because these bacteria have not one but two membranes that shield them against antibiotic attacks. Scientists at Genentech have found a way to penetrate Gram-negative bacteria that they hope will lead to a whole new class of antibiotics. Working in partnership with RQx Pharmaceuticals, they’ve developed a molecule called G0775 and shown ...

Pharmaphorum Media Limited | November 29, 2018

Roche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in inflammatory diseases including the fatty liver disease NASH. Non-alcoholic steatohepatitis (NASH) is a disease targeted by several pharma companies, who see it as a source of billions of dollars in revenue. So far there are no approved treatments for NASH, which is poised to become the leading cause of liver transplants by 2020, as drugs cure more and more patients of...

genengnews | May 17, 2017

Stand Up To Cancer is launching its second SU2C Catalyst™ collaboration in 6 months with Genentech, a member of the Roche Group, with the goal of accelerating development of new cancer treatments and combination therapies....

BioSpace | May 10, 2018

Genentech, a Roche company, reported that its Phase III IMblaze370 trial of Tecentriq (atezolizumab) and Cotellic (cobimetinib) for difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) did not meet its primary endpoint of overall survival (OS) compared to Bayer’s Stivarga (regorafenib).The trial was in patients whose cancer had progressed or who did not tolerate at least two chemotherapy treatments. More than 95 percent of the patients in the study have microsatellite...